 |
About Seattle HPTU |
      |
Overview of the HIV Prevention Trials Network The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network established by the National Institutes of Health (NIH) to evaluate the safety and efficacy of non-vaccine prevention interventions, alone or in combination, using HIV incidence as the primary endpoint. The HPTN is a successor to the HIVNET, a research network that conducted Phase I, II, and III trials at 11 U.S. and 11 international sites. A strong network comprised of three organizations as the leadership group and 25 research sites (16 international and nine domestic) has been assembled to undertake this research. The strengths of the HPTN include:
Models have demonstrated how multiple, mutually reinforcing HIV prevention strategies will have the greatest impact on slowing HIV spread. Because HIV is transmitted through different routes in different populations at different time intervals, the epidemic represents a cumulative collection of heterogenous mini-epidemics. Conceptually, at the population level, multiple prevention strategies are as essential to reducing HIV transmission as combination treatment approaches are at the individual level to improving HIV prognosis. The HPTN will respond to the crucial need for careful evaluation of the most effective non-vaccine HIV prevention approaches that have the greatest impact on slowing viral spread worldwide. For more information on specific studies, explore our research page. |
|
| |